Kalbe

About Kalbe

Kalbe is a global health care company based in Jakarta, Indonesia, established in 1966. Over the years, we have achieved market cap of US$ 5.5 Bn, managed through four business divisions: pharmaceutical, consumer health, nutritional and distribution & logistics. We look forward to explore the opportunities in: small molecules & biologics out and in-licensing;  small volume parenteral & biolog...

Certifications
  • Country/Region:
    Indonesia
  • On CPHI since:
    2018
  • Certificates:
    3
  • Employees:
    5000+
Company types
Contract Service
Distributor/Import Export
Licensee
Manufacturer/Innovator
Primary activities
Biopharmaceutical
Contract Manufacturer
Finished Formulation products Distributor/Buyer
Ingredients Distributor/Buyer
Natural Extracts
Out-licensing specialist
Pharmaceutical Company (generic finished products)
Contact info

Products from Kalbe (3)

  • hyfc EPO (long acting)

    Product hyfc EPO (long acting)

    Efesa, is a long-acting Erythropoietin indicated for CKD-induced anemia in dialysis and non-dialysis patients. Efesa is a hybrid Fc of IgG4 and IgD that provides hinge flexibility and long serum half-life without causing toxicity to target cells. Global Phase 3 trial for non-dialysis indication is currentl...
  • Nimotuzumab

    Product Nimotuzumab

    Nimotuzumab binds with intermediate affinity and high specificity to the extracellular domain of EGFR and blocks the binding of the EGF to its receptor and inhibits tumor cell growth. The molecule induces cell lysis through ADCC mechanism. Nimotuzumab provides vaccinal effect that induce memory T-cell ...
  • Insulin Glargine

    Product Insulin Glargine

    Long-acting basal insulin analogue to treat Type I and II Diabetes Mellitus.

Kalbe Resources (1)